-
Here's What Analysts Are Asking Puma Biotech Following Roche's Positive Perjeta Results
Thursday, March 2, 2017 - 1:07pm | 524Read More...RBC Capital says the commercial opportunity for Puma Biotechnology Inc (NASDAQ: PBYI)’s breast cancer drug neratinib in the extended adjuvant setting should be “considered as eliminated,” given Roche Holding Ltd. (ADR) (OTC: RHHBY)’s positive top-line data for Perjeta....
-
RBC: Sarepta's Setting The Bar Low, Buy On This Weakness
Wednesday, March 1, 2017 - 8:40am | 267Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) slid 15 percent after the company reported Q4 2016 results. The pressure on shares was mainly due to the disappointing guidance, which Sarepta should be able to meet or exceed, RBC Capital Markets’ Simos Simeonidis said in a report. Simeonidis...
-
RBC's Bullish Neurologist Survey Leads To A $108 Price Target On Sarepta Therapeutics
Wednesday, September 28, 2016 - 8:45am | 312Read More...A recent neurologist survey and the latest call with DMD KOLs support a bullish stance on the commercial prospects of Sarepta Therapeutics Inc’s (NASDAQ: SRPT) EXONDYS 51. RBC Capital Markets’ Simos Simeonidis maintained an Outperform rating, while raising the price target from $83...
-
Vivus And Oreixigen Have Too Many Problems For Investors, RBC's Simeonidis Claims
Monday, February 29, 2016 - 11:08am | 358Read More...RBC Capital Markets’ Simos Simeonidis downgraded the ratings for Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc. (NASDAQ: VVUS) from Outperform to Sector Perform, citing a bleak outlook for the obesity segment. Analyst Simos Simeonidis mentioned that the outlook for both the US...
-
Zafgen Doubles: What Do The Experts Think?
Thursday, January 21, 2016 - 12:51pm | 388Read More...Recently, analysts from FBR & Co. and RBC Capital Markets gave their take on Zafgen Inc (NASDAQ: ZFGN) after the company's stock price soared on news that their beloranib drug had positive Phase III data. RBC Capital Markets upgraded Zafgen from Sector Perform to Outperform and raised their...
-
Puma Biotech Sinks On Drug Data; Analyst Upbeat
Tuesday, June 2, 2015 - 3:16pm | 322Read More...Puma Biotechnology Inc (NYSE: PBYI) plunged more than 13 percent on Tuesday after disappointing drug trial results, even as an analyst called the data "clearly positive." The development-stage biopharmaceutical company traded recently at $146.83, off $23.14, on more than three times...
-
Analyst: FDA Won't Pull Permit On Orexigen Therapeutics
Friday, March 6, 2015 - 3:56pm | 307Read More...Orexigen Therapeutics, Inc. (NASDAQ: OREX) sole product, the anti-obesity drug Contrave, almost certainly won't get pulled from the market, an analyst said Friday Orexigen shares fell 12 percent Friday after a regulatory official threatened sanctions on the company for prematurely...
-
Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst
Thursday, March 5, 2015 - 5:02pm | 458Read More...AbbVie Inc's (NYSE: ABBV) $21 billion deal Thursday to buy Pharmacyclics, Inc. (NASDAQ: PCYC) casts a bullish reflection on other potential deals in the industry, an analyst said. Big pharmaceutical companies will pay "what ever price they have to" in acquiring biotech companies...
-
Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT
Thursday, October 3, 2013 - 4:42pm | 122Read More...Cowen and Company analyst Simos Simeonidis upgraded Vivus (NASDAQ: VVUS) from market perform to outperform and raised the PT from $13.50 to $19. Simeonidis reported that the risk/ reward associated with Vivus “appears compelling” as management changes and retail availability of Qsymia suggest a “...
